Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Diwyanshu Sahu"'
Autor:
Drew Watson, Yashaswini S Ullal, Scott C. Howard, Ashish Kumar Agrawal, Michael Castro, Diwyanshu Sahu, Mohammed Sauban, Kabya Basu, Shweta Kapoor, Anusha Pampana, Rakhi Purushothaman Suseela, Anuj Tyagi, Poornachandra G, Yugandhara Narvekar, Adity Ghosh, Prashant Ramachandran Nair, Deepak Anil Lala, Karthik Sundara Raju, Sanjana Patel, Samiksha Avinash Prasad, James Christie, Kunal Ghosh Roy, Nirjhar Mundkur, Swaminathan Rajagopalan, Aftab Alam, Guido Marcucci, Michele Dundas Macpherson
Publikováno v:
Blood. 138:689-689
Background: Although some genomic biomarkers have been integrated into therapeutic decision-making for the management of AML, the complete remission and cure rates have significant margin for improvement. Except for a few targeted therapies, genomic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e24335c185e27199996160bcd63a7a97
https://doi.org/10.1182/blood-2021-154023
https://doi.org/10.1182/blood-2021-154023
Autor:
Mamatha Patil, Naga Ganesh Palaniyeppa, Diwyanshu Sahu, Yashaswini S Ullal, Kabya Basu, Jharana Mohanty, Vishwas Joseph, Upasana Mitra, Scott C. Howard, Mohammed Sauban, Ashokraja Balla, Vijayashree P Shyamasundar, S. Mohapatra, Annapoorna Prakash, Shweta Kapoor, Swati Khandelwal, Guido Marcucci, Liptimayee Behura, Deepak Anil Lala, Michele Dundas Macpherson, Sanjana Patel, Ansu Kumar, Karthik Sundara Raju, Michael Castro, Ashish Kumar Agrawal
Publikováno v:
Blood. 138:3550-3550
Background: Mantle Cell Lymphoma (MCL) accounts for 3-10% of all non-Hodgkin lymphomas with a median overall survival of 3-4 years. Hyper-CVAD (CVAD) with or without Rituximab constitutes first line therapy for treatment of MCL, yet the use of this c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::059d91d4ed7a7e08eac8c4ccd182709f
https://doi.org/10.1182/blood-2021-152423
https://doi.org/10.1182/blood-2021-152423
Autor:
Rakhi Purushothaman Suseela, Ashish Kumar Agrawal, Scott C. Howard, Nirjhar Mundkur, Shweta Kapoor, Ansu Kumar, Prashant Ramachandran Nair, Michael Castro, Vivek R. Shinde Patil, Diwyanshu Sahu, Kabya Basu, Pallavi Kumari, Nagendra K. Prasad, Sanjana Patel, Mohammed Sauban, Archana Palillam Veedu, James Christie, Yashaswini S Ullal, Himanshu Grover, Chandan Kumar, Nithya T Raveendaran, Michele Dundas Macpherson, Anusha Pampana, Samiksha Avinash Prasad, Humera Azam, Anish Raju R Amara
Publikováno v:
Blood. 138:2615-2615
Background: DNA methyltransferase inhibition (DNMTi) with hypomethylating agents (HMA), azacitidine (AZA) or decitabine (DAC), remains the mainstay of therapy for most high-risk Myelodysplastic syndrome (MDS) patients. However, only 40-50% of MDS pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1970903484a6dda996fc07532b0404bf
https://doi.org/10.1182/blood-2021-153220
https://doi.org/10.1182/blood-2021-153220
Autor:
Drew Watson, Yashaswini S Ullal, Himanshu Grover, Shweta Kapoor, James Christie, Liptimayee Behura, Annapoorna Prakash, Prashant Ramachandran Nair, Michele Dundas Macpherson, Veena Balakrishnan, Rajan Parashar, Kunal Ghosh Roy, Aftab Alam, Diwyanshu Sahu, Kabya Basu, Yugandhara Narvekar, Adity Ghosh, Anthony S. Stein, Guido Marcucci, Swaminathan Rajagopalan, Nirjhar Mundkur
Publikováno v:
Blood. 136:9-10
Background: Therapy selection for MDS patients is often based on information considering only cytogenetics and single molecular aberrations and ignoring other patient-specific omics data that could potentially enable more effective treatments. In tur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bd7bd7914f0bdbf3ee4e8cc0b58a924
https://doi.org/10.1182/blood-2020-142214
https://doi.org/10.1182/blood-2020-142214
Autor:
Jim Christie, Prashant Ramachandran Nair, Manmeet Ahluwalia, Drew Watson, Yashaswini S Ullal, Michael Castro, Vamsidhar Velcheti, Shweta Kapoor, Aftab Alam, Adity Ghosh, Mohammed Sauban, Rakhi Purushothaman Suseela, Shruthi Kulkarni, Anuj Tyagi, Diwyanshu Sahu, Kabya Basu, Kunal Ghosh Roy, Swaminathan Rajagopalan, Nirjhar Mundkur
Publikováno v:
Journal of Clinical Oncology. 39:9117-9117
9117 Background: The Cellworks Singula Therapeutic Response Index (TRI) has been developed to assist clinicians and NSCLC patients in choosing between competing therapeutic options. In contrast to approaches that consider single aberrations, which of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2065e1963f96da4702da90276b34bc78
https://doi.org/10.1200/jco.2021.39.15_suppl.9117
https://doi.org/10.1200/jco.2021.39.15_suppl.9117
Autor:
Manmeet Ahluwalia, Sayani Basu, Prashant Ramachandran Nair, Shweta Kapoor, Yugandhara Narvekar, Michael Castro, Diwyanshu Sahu, Patrick Y. Wen, Kabya Basu, Ashish Kumar Agrawal, Divya Singh, Deepak Anil Lala, Drew Watson, Kunal Ghosh Roy, Nirjhar Mundkur, Swaminathan Rajagopalan, Anusha Pampana, Jim Christie, Aftab Alam
Publikováno v:
Journal of Clinical Oncology. 39:2017-2017
2017 Background: The Cellworks Singula Therapeutic Response Index (TRI) has been developed to assist clinicians and GBM patients in choosing between competing therapeutic options. In contrast to approaches that consider single aberrations, which ofte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b07fa82a9f7f575392e009cf06365b8e
https://doi.org/10.1200/jco.2021.39.15_suppl.2017
https://doi.org/10.1200/jco.2021.39.15_suppl.2017
Autor:
Poornachandra G, Drew Watson, Scott C. Howard, Himanshu Grover, Diwyanshu Sahu, Michael Castro, Michele Dundas Macpherson, Chandan Kumar, Naga Ganesh, Sayani Basu, S. Mohapatra, Ansu Kumar, Ashish Agarwal, Nirjhar Mundkur, Rakhi Purushothaman Suseela, Rahul K Raman, Divya Singh, Mohammed Sauban, Neelesh Lunkad, Prashant Ramachandran Nair, Shweta Kapoor
Publikováno v:
Blood. 136:9-9
Background: Monosomy 7/Del 7 (-7) or its long arm (del(7q)) is one of the most common cytogenetic abnormalities in pediatric and adult myeloid malignancies, particularly in adverse-risk acute myeloid leukemias (AMLs). In general, (-7) is associated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74ce9ad8177d02c1d37a9d6287527546
https://doi.org/10.1182/blood-2020-140087
https://doi.org/10.1182/blood-2020-140087
Autor:
Swaminathan Rajagopalan, Nirjhar Mundkur, Prashant Ramachandran Nair, Anish Raju R Amara, Diwyanshu Sahu, Kabya Basu, Aftab Alam, James Christie, Shweta Kapoor, Rajan Parashar, Adity Ghosh, Drew Watson, Yashaswini S Ullal, Michele Dundas Macpherson, Yugandhara Narvekar, Himanshu Grover, Anusha Pampana, Anthony S. Stein, Guido Marcucci, Kunal Ghosh Roy
Publikováno v:
Blood. 136:35-35
Background. In addition to clinical considerations (e.g., age, de novo vs secondary disease, comorbidities), therapy selection for AML patients is often based on information considering only cytogenetics and/or molecular aberrations and ignoring othe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68ade65459b57cd55ecee056ac2f1930
https://doi.org/10.1182/blood-2020-142184
https://doi.org/10.1182/blood-2020-142184
Autor:
Vishwas Joseph, Kunal Ghosh Roy, Drew Watson, Shivgonda C. Birajdar, Diwyanshu Sahu, Yashaswini S Ullal, Annapoorna Prakash, Kabya Basu, Sayani Basu, Karthik Sundara Raju, Chandan Kumar, R. Gopi, Aftab Alam, S. Mohapatra, Anthony S. Stein, Pallavi Kumari, Shweta Kapoor, Guido Marcucci, Rakhi Purushothaman Suseela, Upasana Mitra
Publikováno v:
Journal of Clinical Oncology. 38:e19528-e19528
e19528 Background: Despite using cytogenetic and molecular-risk stratification and precision medicine, the current overall outcome of MDS patients remains relatively poor. Therapy selection is often based on information considering only cytogenetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98ce11a90ea84a4fa6fb56cf5be6bcae
https://doi.org/10.1200/jco.2020.38.15_suppl.e19528
https://doi.org/10.1200/jco.2020.38.15_suppl.e19528
Autor:
Prashant Ramachandran Nair, Kunal Ghosh Roy, Aftab Alam, Gordon T Moffat, Nikita Ray Choudhary, Neha Gupta, Shweta Kapoor, Anuj Tyagi, Zakir Husain, Preethi Elangovan, Eileen M. O'Reilly, Nirjhar Mundkur, Pallavi Kumari, Vijayashree P S, Diwyanshu Sahu, Aktar Alam, Drew Watson, Rema Mandal, Rajan Parashar, Divya Singh
Publikováno v:
Journal of Clinical Oncology. 38:e16766-e16766
e16766 Background: Current therapy for PDAC is modestly effective. Therapy selection guidelines are typically limited to single aberrations and ignore relevant patient-specific omics. These alterations create patient-specific resistance pathways that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0728daa2f1ee949fbb6fbb5bbbacebe
https://doi.org/10.1200/jco.2020.38.15_suppl.e16766
https://doi.org/10.1200/jco.2020.38.15_suppl.e16766